Chemiluminescence of the Reaction System Ce(IV) - Non-Steroidal Anti-Inflammatory Drugs Containing Europium(III) Ions and its Application to the Determination of Naproxen in Pharmaceutical Preparations and Urine

Małgorzata Kaczmarek

Abstract The chemiluminescence (CL) of oxidation of non-steroidal anti-inflammatory drugs (NSAIDs) by Ce(IV) ions, was recorded in the presence and absence europium(III) ions, in solution of pH ~4 of solution. Kinetic curves and CL emission spectra of the all studied systems were discussed. CL of measurable intensity was observed in the Ce(IV)-NP-Eu(III) reaction system only in acidic solutions. The CL spectrum registered for this system shows emission bands, typical of Eu(III) ions, with maximum at λ~600 nm. The chemiluminescent method, based on Eu(III) emission in reaction system of NP-Ce(IV)-Eu(III) in acid solution was therefore used for the determination of naproxen in mixture of non-steroidal anti-inflammatory drugs.

Keywords Chemiluminescence · Europium · Non-steroidal anti-inflammatory drugs

Introduction

Naproxen(NP), ibuprofen(IB) and indomethacin (IM) are non-steroidal anti-inflammatory drugs (NSAID). Chemically, NP and IB belong to the 2-arylpropionic acid family, whereas IM belongs to the class of aryacetic acid. The NSAID as a group are diverse in chemical structure but are consistent in their ability to inhibit the enzyme cyclooxygenase, regarded as a marker for inflammation [1]. The complexion processes of naproxen(NP) or ibuprofen(IB) or indomethacin (IM) with lanthanide ions depend of pH values. In acidic solution, the degree of complexation is small [2]. The trivalent lanthanide ions, especially Eu(III) and Tb(III), display spectroscopic properties of high photoluminescence efficiencies, long excited-state lifetimes band narrow emission spectra, all of which make them be widely used as analytical luminescent probes for a variety of chemical and biological applications [3–5].

Chemiluminescence can be achieved by direct reactions or by energy-transfer mechanisms. The CL phenomenon can be applied as detection technique for the monitoring of a wide variety of compounds in diverse fields, such as biomedical, environmental and can be considered as an alternative to other detection modes such as: UV/Vis spectroscopy, fluorescence [6]. In this work, the use of sensitized chemiluminescence of lanthanide ions for determination of naproxen in mixture of NSAIDs is studied. It was observed that only the CL signal of the Ce(IV)- Naproxen system was significantly increased in the presence of Eu(III) ions.

Experimental

Ultra weak photon emission was recorded with the use of the earlier described equipment [7]. The fluorescence spectra were recorded using F-7000 HITACHI spectrofluorimeter.

Chemicals

All chemicals used were of analytical reagent grade and doubly distilled water was used throughout the experi-
ments. Naproxen sodium and indomethacin were from Sigma, ibuprofen sodium was from Fluka.

Their stock standard solutions ($2 \times 10^{-3}$ mol L$^{-1}$) were prepared by dissolving appropriate amounts of naproxen sodium and ibuprofen sodium in water and diluting to 100 ml with water. A stock standard solution of indomethacin ($6 \times 10^{-4}$ mol L$^{-1}$) was prepared by dissolving an appropriate amount of IM with 0.1 mol L$^{-1}$ hydrochloric acid and then diluting to 100 ml with water. Working standard solutions of naproxen sodium were prepared of diluted the stock solution with water.

Optimization of Experimental Conditions

The optimum conditions for the naproxen determinations were carried out using the $1 \times 10^{-6}$ mol L$^{-1}$ concentration of NP. The effect of Ce(IV) concentration on the CL reaction was examined in the range of $5.0 \times 10^{-4}$ to $4.0 \times 10^{-3}$ mol L$^{-1}$ in 0.015, 0.025, 0.05, 0.15 or 0.3 mol L$^{-1}$ H$_2$SO$_4$. The most integrated CL light sum was obtained when the concentration of Ce(IV) was $2.0 \times 10^{-3}$ mol L$^{-1}$ in 0.015 mol L$^{-1}$ H$_2$SO$_4$. For the NP-Ce(IV)-Eu(III) system, the optimum concentration of europium(III) ions, using the following range of concentrations $1.0 \times 10^{-4}$ - $1.0 \times 10^{-2}$ mol L$^{-1}$ was determined. In the case of concentration of Eu (III) ions above $1.0 \times 10^{-3}$ mol L$^{-1}$ the CL light intensity sums did not change, so as the optimal concentration of Eu (III) ions for the determination of NP $2.0 \times 10^{-3}$ mol L$^{-1}$ was chosen.

Measurement Procedure

All of the chemiluminescence studies were performed in the same manner. Solution of cerium(IV) ions was added to solutions containing NSAID (1 mL solutions of appropriate concentrations) or NSAID and Eu(III) ions. The experiments were conducted in acidic solutions (pH ~4). The total volume was 4 mL. The determination of naproxen in water, pharmaceutical preparations was carried out measuring the CL light intensity sums of the reaction systems applying the cut-off filters method, with the use of a filter transmitting emission of $\lambda > 585$ nm, which was placed between the photomultiplier and the measurement cell. CL light intensity sums were calculated as the area under these curves [4].

Sample Preparation

Tablets Not less than 10 tablets were weighed and finely powdered. Specific amounts of analyte were weighed accurately, dissolved in water in a small beaker. The solution was filtered, and the residue was washed with water several times. Then it was transferred into a 250 mL calibrated flask and diluted to the specified volume with water. Working solutions were prepared by appropriate dilution of this sample solution so that the final analytic concentrations were within the working range.

Ointment Accurately weighed out amount of the ointment was dissolved in water (40 °C) and 1 mL 0.1 mol L$^{-1}$ NaOH while vigorously mixing. Next the solution was cooled in a refrigerator, in order to separate from vaseline, and transferred into a 100 ml calibrated flask and diluted to volume with water. The final concentration of NP was within the working range.

Urine

Urine samples were obtained from two healthy volunteers. Known amounts of standard solutions of naproxen were introduced into 1 mL of fresh urine samples. The typical naproxen urinary concentration was 0.2–20 μg/ml [8]. This urine sample was mixed with a 10 mL of 0.1 mol L$^{-1}$ Ba (OH)$_2$ solution and a 9 mL of 0.1 mol L$^{-1}$ ZnSO$_4$ solution in order to remove protein and reducing substances [9, 10]. The resulting solution was diluted to 50 mL with doubly distilled water and centrifuged at 3000 for 15 min. The supernatant solution was stored and maintained below 5 °C. For analysis 1 mL of solution was used.

Results and Discussion

Effect of Presence of the Europium(III) Ions on the CL Intensity of the Ce(IV)-NSAID Systems

The chemiluminescence of systems containing NP or IB or IM and Ce(IV) ions as oxidizer in solution at pH ~4 in the absence and in the presence europium(III) ions were studied. Chemiluminescence in the system NSAID-Ce(IV) was obtained, when the concentration of NSAID was higher than $2 \times 10^{-7}$ mol L$^{-1}$ for NP and $4 \times 10^{-3}$ mol L$^{-1}$ for IB and $2 \times 10^{-4}$ mol L$^{-1}$ for IM. For all systems the course of the kinetic curves of CL were similar, with maximum after initiation of the reaction by introducing Ce (IV) ions. The emission at the level of the background was obtained in about 30 s after the reaction initiation. Introduction of Eu(III) ions into the system NSAID-Ce (IV) resulted in a strong increase in the emission intensity only in the system containing naproxen without a change in the kinetic curve character (curves 3 and 4 in Fig. 1). The intensity of CL of the systems IB-Ce(IV) and IB-Ce(IV)-Eu (III) or IM-Ce(IV) and IM-Ce(IV)-Eu(III) were the same.
The kinetics of the chemiluminescence decay of NP-Ce(IV) and NP-Ce(IV)–Eu(III) were monoexponential.

Spectral analysis of the chemiluminescence in the systems studied was performed using the method of cut-off filters as described earlier [11]. The spectra show a broad emission band in the range 400–600 nm, with a maximum at \( \lambda \approx 450 \) nm for NP and 480 nm for IM or 420 nm for IB, which is typical of the CL systems with the compounds containing excited carbonyl groups as emitters [12]. The spectral distribution of CL of the NP-Ce(IV)-Eu(III) system dependent on the concentration of europium(III) ions. The spectral distribution, observed for the molar ratio Eu: NP=10:1, shows a broad band at 450 nm and a second band centered at \( \lambda = 600 \) nm (spectrum 2 in Fig. 2) corresponding to the \( ^5D_0 \to ^7F_1 \) and \( ^5D_0 \to ^7F_2 \) transition of the Eu(III) ion [13]. For higher molar ratio (Eu: NP above 100:1) the dominant band is band typical for Eu(III) with a maximum at \( \lambda \approx 600 \) nm (spectrum 4 in Fig. 2). This means that the presence of the lanthanide ion is responsible for the increase in the CL intensity of NP-Ce(IV)-Eu(III) system.

In order to identify the role of the lanthanide ion in the reaction mixture NP-Ce(IV)-Eu(III), the process of Ln(III) complexation with NP in the pH range about 4–5 was studied. In the investigated pH region for all of the molar ratios used (Eu: NP=10:1; 40:1 and 100:1) the luminescence of Eu(III) was not observed, applying \( \lambda_{\text{ex}} \) typical for NP, i.e.: 270 nm, 317 nm and 327 nm. The recorded luminescence spectra show only one large unstructured band centered at around 353 nm (spectra 1, 2, 3 in Fig. 3), typical for this drug [14]. Using \( \lambda_{\text{ex}} = 394 \) nm (typical for Eu(III) ions) the same luminescence spectrum (spectrum 4 in Fig. 3) as in the case of EuCl\(_3\) solution was obtained, which is typical for uncomplexed Eu(III) ions [11]. This indicates that the complex formation did not occur place in the chemiluminescent reaction system NP-Ce(IV)-Eu(III).

As follows from Fig. 1 the presence of Eu(III) ions have no effect on the rate of the naproxen oxidation with cerium (IV) ions. In the chemiluminescent experimental conditions europium(III) ions are uncomplexed and because of that a ligand to metal transfer process cannot appear (Fig. 3). The presence of europium(III) bands in the CL spectrum of the NP-Ce(IV)-Eu(III) system indicates that the excitation of Eu(III) ions in the reaction mixture is a result of the energy transfer process from the excited product of NP oxidation to the uncomplexed Eu(III) ions.

Oxidative decarboxylation of substituted phenylacetic acids can be mediated by metallic and nonmetallic oxidants or by electrolytic means [15]. When naproxen was treated with cerium (IV) or peroxodisulfate, the product pattern was similar to that from photolysis [16]. The major photoproducts obtained by irradiation of the drug under aerobic conditions are 6-methoxy-2-(1-hydroxyethyl)-naphthalene and 6-methoxy-2-acetyl-naphthalene, and a...
small amount of 6-methoxy-2-ethyl-naphthalene. The 6-methoxy-2-acetyl-naphthalene shows the emission band centered at around 440 nm [17], which correspond to the chemiluminescent spectrum.

Analytical Application

The reaction mixture of NP-Ce(IV)-Eu(III) was used for the determination of the naproxen concentration, with applying the cut-off filters method. A linear dependence of the CL light intensity sums of the reaction system on the NP concentration, with the use of a filter transmitting emission of $\lambda > 585$ nm, was obtained in the NP concentration range of $4 \times 10^{-8}$ molL$^{-1}$ (9 ng/mL) to $2 \times 10^{-6}$ molL$^{-1}$ (460 ng/mL) (correlation coefficient $r=0.9998$) with the detection limit of $1.1 \times 10^{-8}$ molL$^{-1}$ (2.5 ng/mL). It is six times lower than determination in reaction system without europium(III) ions [18].

Interference

The effect of some common inorganic ion and excipient species on the determination of $2.0 \times 10^{-7}$ molL$^{-1}$ naproxen solution was studied. The tolerance limit was taken as the recovery in the range 95%–105%. The tolerance ratios were as follows: 5000-fold for indomethacin, ibuprofen, K(I), Na(I), Mg(II), Ca(II); Zn(II); NO$_3^-$, SO$_4^{2-}$; 500-fold for CO$_3^{2-}$; 100-fold for Fe(III) starch, glycine, glucose; and 30-fold for Fe(II). These tolerance ratios were higher than in system without europium(III) ions [18].

Applications

The proposed method was applied to the determination of Naproxen in commercially available pharmaceuticals. The obtained results are shown in Table 1. As can be seen, there are no significant differences between the labeled values and those obtained by the suggested method. A mean recovery values were in the range 98–104%.

The accuracy studies for the determination of naproxen in human urine were conducted with three known concentrations of the compound. Results of recovery studies for urine are given in Table 2. Each value represents the mean of five measurements.

Conclusion

The reaction system NSAID-Ce(IV) belongs to the group systems generating ultra-weak emission characteristic for excited carbonyl species formed as a result of NSAID oxidation. The presence of Eu(III) ions into the systems of IB-Ce(IV) and IM-Ce(IV) did not influence on CL intensity, however the Eu(III) ions are effective activators in the NP-Ce(IV) system. The CL reaction system of NP-Ce(IV)-Eu(III), as these studies have shown, can be analytically useful. This method gives a lower detection limit and a large tolerance of on the presence of inorganic ion and excipient species compared with the NP-Ce(IV) system. The proposed chemiluminescent method, based on emission of the Eu(III) ions in the NP-Ce(IV)-Eu(III) system, is simple, accurate and precise and allows the determination of naproxen in pharmaceutical preparations and in human urine.

Acknowledgments

Financial support from the Polish Ministry of Science and Higher Education; Grant NN204 028236 is gratefully acknowledged.

| Drug sample      | Label Amount (mg) | Found by proposed method (mg±S.D.) | Recovery [%] |
|------------------|-------------------|------------------------------------|--------------|
| APO-NAPROXEN     | 250 mg            | 249±3                              | 99.6±1.2     |
| ALEVE            | 220 mg            | 222±4                              | 101.4±1.8    |
| NAPROXEN         | 500 mg            | 495.5±7                            | 99.1±1.4     |
| NAPROXEN         | 250 mg            | 255.3±3                            | 102.1±1.2    |
| NAPROXEN EMO gel | 100 mg g$^{-1}$   | 101.8±2 mg g$^{-1}$                | 101.8±2      |

Table 1 Determination of naproxen in commercial formulations with the proposed CL method ($n=5$)

| Sample          | Added$^a$ (µg/ml) | Found±SD (µg/ml) | Recovery±SD (%) |
|-----------------|-------------------|------------------|-----------------|
| Urine-1         | 2                 | 2.04±0.04        | 102±2           |
|                 | 4                 | 4.02±0.06        | 100.5±1.5       |
|                 | 10                | 9.82±0.16        | 98.2±1.6        |
| Urine-2         | 2                 | 1.98±0.04        | 99±2            |
|                 | 6                 | 6.02±0.07        | 100.3±1.2       |
|                 | 14                | 14.30±0.15       | 102.1±1.1       |

$^a$ in undiluted urine

Table 2 Determination of naproxen in human urine with the proposed CL method
References

1. Vane JR, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44(1):1–10
2. Telyuk OI, Beltuykova SV, Yegorova AV, Yagodkin BN (2007) Complex compounds of terbium(III) with some non-steroidal anti-inflammatory drugs and their analytical applications. J Anal Chem 62(4):330–335
3. Li D, Du J, Lu J (2008) Europium(III)-sensitized chemiluminescence determination of ibuprofen in pharmaceutical preparations and biological fluids. Anal Letters 41(8):1366–1374
4. Kaczmarek M, Lis S (2009) Chemiluminescence determination of tetracyclines using Fenton system in the presence europium(III) ions. Anal Chim Acta 639(1–2):96–100
5. Al-Kindy SMZ, Suliman FEO (2007) Determination of ibuprofen in pharmaceutical formulations using time-resolved terbium-sensitized luminescence. Luminescence 22(4):294–301
6. Gámiz-Gracia L, García-Campaña AM, Huertas-Pérez JF, Lara FJ (2009) Chemiluminescence detection in liquid chromatography: Applications to clinical, pharmaceutical, environmental and food analysis—A review. Anal Chim Acta 640(1–2):7–28
7. Kaczmarek M, Lis S (2006) Luminescence characterization of the reaction system Histidin – KBrO3 – Tb(III) – H2SO4. J Fluorescence 16(6):825–830
8. Aresta A, Palmisano F, Zambonin CG (2005) Determination of naproxen in human urine by solid-phase microextraction coupled to liquid chromatography. J Pharm Biomed Anal 39(3–4):643–647
9. Malavolti NL, Pilosol D, Nieman TA (1985) Determination of cholesterol with a microporous membrane chemiluminescence cell with cholesterol oxidase in solution. Anal Chim Acta 170:199–207
10. Wang X, Zhao H, Nie L, Jin L, Zhang Z (2001) Europium sensitized chemiluminescence determination of rifloxacin. Anal Chim Acta 445(2):169–175
11. Staninski K, Kaczmarek M, Lis S, KomarD SA (2009) Spectral analysis in ultraweak emissions of chemi- and Electrochemiluminescence systems. J Rare Earths 27(4):593–597
12. Ostakhov SS, Sharipov GL, Volkoshin AI, Kazakov VP, Tolstikov GA (1986) Catalysis and sensitization of chemiluminescence at thermal decomposition of adamantylidene-adamantane-1,2-dioxetane by Tb, Eu and Ru compounds. Dokl Akad Nauk SSSR 287:1165–1168
13. Lis S (2002) Luminescence studies of lanthanide(III) ions in solution. J Alloys Comp 341(1–2):45–50
14. Velázquez MM, Valero M, Rodriguez LJ, Costa SMB, Santos MA (1995) Hydrogen binding in a non-steroidal anti-inflammatory drug, Naproxen. J Photochem Photobiol B Biol 29(1):23–31
15. Tanner DD, Osman SAA (1987) Oxidative decarboxylation. on the mechanism of the potassium persulfate promoted decarboxylation reaction. J Org Chem 52(21):4689–4693
16. Bosca F, Martinez-Manez R, Miranda MA, Primo J, Soto J, Vano L (1992) Oxidative decarboxylation of naproxen. J Pharm Sci 81(5):479–482
17. Valero M, Carrillo C (2004) Effect of binary and ternary polyethylene glycol and/or β-cyclodextrin complexes on the photochemical and photosensitizing properties of naproxen. J Photochem Photobiol B Biol 74(2–3):151–160
18. Campiglio A (1998) Determination of naproxen with chemiluminescence detection. Analyst 123(7):1571–1574